Trial Profile
Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary) ; Adefovir; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- 06 Jan 2011 New trial record